
NM_000245.4 (MET):c.1063G>A (p.Glu355Lys) AND Renal cell …
Dec 2, 2021 · This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 355 of the MET protein (p.Glu355Lys). This variant is …
Evidence Repository - Clinical Genome Resources
Feb 10, 2021 · The functional impact has been assessed by transfection in CHO cells, showing lack of αIIbβ3 surface expression with the Glu355Lys mutant (PMIDs: 11122161, 12362239).
UniProtKB/SwissProt variant VAR_009888
Residue change: From Glutamate (E) to Lysine (K) at position 355 (E355K, p.Glu355Lys). Indicates the amino acid change of the variant.
Genetic Variant SGSH:p.Glu355Lys (chr17-80210898-C-T) – ACMG ...
This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 355 of the SGSH protein (p.Glu355Lys). This variant is present in …
a, b LC-MS/MS TIC chromatograms the glycosaminoglycans in …
Peak 2: heparin disaccharide I-S. c Main results of whole exome sequencing identifying SGSH heterozygous G > A change at nucleotide c.1063G > A (p.Glu355Lys, OMIM: 252900, …
VCV002053225.2 - ClinVar - NCBI
This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 355 of the FH protein (p.Glu355Lys). This variant is not present in …
Genetic Variant IFIH1:p.Glu355Lys (chr2-162288167-C-T) – ACMG ...
This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 355 of the IFIH1 protein (p.Glu355Lys). This variant is not present in …
Structural basis of fumarate hydratase deficiency
Mar 29, 2011 · Fumarate hydratase deficiency is an autosomal recessive trait presenting as metabolic disorder with severe encephalopathy, seizures and poor neurological outcome. …
Aug 18, 2021 · understanding of the neuronal pathogenesis associated with GM3SD.
Structural basis of fumarate hydratase deficiency - PMC
Fumarate hydratase deficiency is an autosomal recessive trait presenting as metabolic disorder with severe encephalopathy, seizures and poor neurological outcome. Heterozygous …